We are hereby submitting the trading approvals received from BSE and NSE vide their letters dated February 04, 2026 for the Equity shares allotted under Rights Issue of the Company.
VINEETLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vineet Laboratories has informed the exchanges that BSE and NSE have granted trading approval, via letters dated February 4, 2026, for the equity shares allotted under the company's recent Rights Issue. This means the newly issued shares are now officially listed and can be bought and sold on both stock exchanges. Until this approval came through, the rights issue shares were allotted but not tradable. The filing is a routine procedural update confirming exchange-level clearance post-allotment.
For shareholders who subscribed to the rights issue, their allotted shares can now be traded normally, improving liquidity. This is a standard post-issue compliance filing and is not expected to have a material impact on the stock price by itself, though the increased share count is now fully part of the tradable float.